RNS & Investor News

Director/PDMR Shareholding

24 September 2025

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces that the Company has been informed that Stephen O'Hara, a Director of the Company, made the following purchases of ordinary shares in the capital of the Company. Further details are set out in the Notification of Dealing Form below.

 

Director

Purchase price (Aggregated)

Ordinary shares purchased

Resultant interest in ordinary shares

Resultant percentage of issued ordinary shares

Stephen O'Hara

10.13 pence

195,238

10,408,224

10.08%

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

 

Stephen O'Hara, Chief Executive


 

 

Cairn Financial Advisers LLP (NOMAD and Broker)

Tel: 020 7213 0880

Liam Murray / Ludovico Lazzaretti / James Western


 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Stephen O'Hara

2

Reason for notification


a.

Position/Status

Director - Chief Executive Officer

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI


4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares

 

c.

Price(s) and volume(s)




Price(s) per share

Volume(s)


9.77p

50,000



9.78p

50,000



d.

Aggregated information

-       Volume

-       Price

 

100,000 shares

9.77 pence per share

e.

Date of the transaction

22 September 2025

f.

Place of the transaction

London

 

>

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Stephen O'Hara

2

Reason for notification


a.

Position/Status

Director - Chief Executive Officer

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI


4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares

 

c.

Price(s) and volume(s)




Price(s) per share

Volume(s)


10.5p

47,619



10.5p

47,619



d.

Aggregated information

-       Volume

-       Price

 

95,238 shares

10.5 pence per share

e.

Date of the transaction

23 September 2025

f.

Place of the transaction

London